Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir concentrations and antiviral activity in cerebrospinal fluid in HIV-1 infected individuals
2018-000302-39Phase 3Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bictegravir in human immunodeficiency virus infection (HIV), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoints: Total bictegravir concentration in cerebrospinal fluid, Unbound bictegravir concentration in cerebrospinal fluid and 1 more. Started Apr 2018; status: completed.
02
Drugs
bictegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-000302-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000302-39.